Editor: What To Know
- in Computer Science and Engineering from the University of California San Diego and an M.
- These two additions to the team are instrumental in building the infrastructure and systems to scale the company to meet the clinical demand.
- Prior to joining the MedTech industry, he spent nine years in equity research on Wall Street, most recently as head of MedTech research at Lazard, Ltd.
June 23, 2020
Carlsmed announced the close of an oversubscribed $2.5M seed round. The round was led by Cove Fund II, a prominent California Life Science and Technology fund.
Carlsmed notes participating in the round are MedTech funds Wavemaker Three-Sixty Health and Device of Tomorrow Capital, as well as individual MedTech investors.
We are very bullish about the prospects for Carlsmed,” said Mike Benvenuti, Co-Manager of Cove Fund II. “Carlsmed’s team has the deep industry experience and operational expertise to lead the much-needed shift to personalized medicine for challenging complex spine cases and beyond.”
“This round of venture financing accelerates the clinical launch of the aprevo™ system,” said Mike Cordonnier, CEO, and co-founder of Carlsmed. “Surgeons and patients across the spectrum that have postponed treatment for debilitating spinal conditions will soon have access to an affordable and streamlined system for personalized spine surgery.”
Today, Carlsmed also announced the appointment of Alexander Arrow, MD, CFA, as Chief Financial Officer and Shariq Hussain as Chief Information Officer, leading the company’s digital development and operations. These two additions to the team are instrumental in building the infrastructure and systems to scale the company to meet the clinical demand.
Dr. Arrow is a MedTech executive with 20+ years of C-suite and financial leadership roles including CFO of Protagenic Therapeutics, Inc. (PTIX), CEO of Zelegent, Inc., and President, COO, and Director of Biolase, Inc. (BIOL). Dr. Arrow also served as Chief Medical Officer of Stanford-affiliated neuroscience company Circuit Therapeutics, Inc., and as CFO of cardiovascular device manufacturer Arstasis, Inc. He also spent two years as CFO of the Patent & License Exchange, Inc. Prior to joining the MedTech industry, he spent nine years in equity research on Wall Street, most recently as head of MedTech research at Lazard, Ltd. He has an M.D. from Harvard Medical School and a B.A. in Biophysics from Cornell University.
Mr. Hussain is a serial entrepreneur in the MedTech industry. As co-founder, and past CEO and CTO, of IntelliGuard, he developed fully integrated hospital inventory management solutions of high-value pharmaceuticals. Previously, he led Systems Integration and Cybersecurity for startup Safety Syringes, which resulted in its successful acquisition by Becton Dickinson. He has a B.S. in Computer Science and Engineering from the University of California San Diego and an M.B.A. from National University.
